Organ-on-chip technologies are emerging as powerful tools to model human physiology and to support evidence-based evaluation of both therapeutic and natural products. In gastroesophageal reflux disease (GERD), where microscopic mucosal damage can drive symptom generation despite the absence of visible lesions, topical mucosal protectants represent a promising therapeutic approach. The integration of advanced millifluidic systems with phytotherapeutic expertise offers new opportunities to accelerate the development of scientifically substantiated natural health solutions.
Through a strategic collaboration between React4life and Prodeco Pharma, the MIVO® esophagus-on-chip platform was used to evaluate the protective and reparative effects of a novel botanical mucosal protectant (GSE Reflusolve Rapid) in a physiologically relevant GERD model, compared with an alginate/carbonate-based benchmark. The dynamic system enabled controlled acid exposure and quantitative assessment of epithelial responses. Both formulations preserved epithelial integrity, mitigating TEER reduction, FITC-dextran permeability, and microscopic tissue damage. The botanical product demonstrated superior anti-inflammatory activity, significantly reducing IL-8 secretion, and promoted a stronger and more uniform MUC5B expression during tissue repair.
Overall, these findings highlight the potential of GSE Reflusolve Rapid as a scientifically supported option for long-term symptom management in GERD, while underscoring the value of MIVO® organ-on-chip technology in validating the efficacy of natural remedies and advancing sustainable, animal-free research.

In collaboration with: